Tweet
Expert Opin Investig Drugs. 2019 Apr 24:1-8. doi: 10.1080/13543784.2019.1606210. [Epub ahead of print]
Investigational antiviral therapies for the treatment of influenza.
Yang J1, Huang Y1, Liu S1,2.
Author information
Abstract
Influenza viral ribonucleoprotein complexes (vRNPs) play a key role in viral transcription and replication; hence, the recent development of novel anti-influenza drugs targeting vRNPs has garnered widespread interest. Areas covered: We discuss the function of the constituents of vRNPs and summarize those vRNPs-targeted synthetic drugs that are in preclinical and early clinical development. Expert opinion: vRNPs contain high-value drug targets; such targets include the subunits PA, PB1, PB2, and NP. Developing a new generation of antiviral therapies with strategies that utilize existing drugs, natural compounds originated from new resources and novel drug combinations may open up new therapeutic approaches to influenza.
KEYWORDS:
Baloxavir; influenza virus; inhibitor; vRNPs
PMID: 31018720 DOI: 10.1080/13543784.2019.1606210
Investigational antiviral therapies for the treatment of influenza.
Yang J1, Huang Y1, Liu S1,2.
Author information
Abstract
Influenza viral ribonucleoprotein complexes (vRNPs) play a key role in viral transcription and replication; hence, the recent development of novel anti-influenza drugs targeting vRNPs has garnered widespread interest. Areas covered: We discuss the function of the constituents of vRNPs and summarize those vRNPs-targeted synthetic drugs that are in preclinical and early clinical development. Expert opinion: vRNPs contain high-value drug targets; such targets include the subunits PA, PB1, PB2, and NP. Developing a new generation of antiviral therapies with strategies that utilize existing drugs, natural compounds originated from new resources and novel drug combinations may open up new therapeutic approaches to influenza.
KEYWORDS:
Baloxavir; influenza virus; inhibitor; vRNPs
PMID: 31018720 DOI: 10.1080/13543784.2019.1606210